Endocrine Abstracts

Background: Psychopathological distress is a significant burden in acromegaly, mostly in terms of depression and anxiety. Patients are also reported to experience an impairment in cognitive performance, yet literature is highly heterogeneous.M&M: We conducted a cross-sectional study recruiting 44 acromegalic patients (59% females, 29.5% with active disease, 70.5% controlled/in remission) referring to our tertiary center between 2011 and 2023 and 40 h...

Background: In the last few decades, the association between pituitary disorders and cardiovascular disease has been demonstrated. Furthermore, the importance of gender as a non-modifiable risk of factor is increasingly emerging.Methods: We retrospectively analyzed data of 112 patients diagnosed with nonfunctioning pituitary tumor (NFPT) attending the outpatient clinic at our tertiary center. In this study we report only preliminary data of the retrospec...

Alternative splicing is a crucial mechanism of gene regulation and this process can be dysregulated in cancer. In pituitary tumors (PitNETs), alteration in the serine/arginine-rich splicing factors (SRSFs) has been reported. Newly synthetized SRSFs are phosphorylated by serine-arginine protein kinase 1 (SRPK1) to facilitate their nuclear import. In response to extracellular stimuli SRPK1 may translocate to the nucleus as well to hyperphosphorylate SRSFs and favor their interac...

Introduction: Adults with growth hormone deficiency (AGHD) have increased prevalence of hepatic steatosis (HS) that might be improved by growth hormone replacement therapy (rhGH). However, data on this topic are conflincting and scanty. Aim: to evaluate prevalence of HS, organ-specific distribution of adipose tissue and cardiovascular impairment in AGHD.Methods: cross-sectional collection of clinical, biochemical and instrumental data (abdominal ultrasou...

The aim of this study was to evaluate in a long follow-up time patients with acromegaly successfully treated by transphenoidal surgery (TNS) in order to establish the recurrence rate and the need of subsequent follow up.Methods: We retrospectively analyzed data of 283 acromegalic patients (168 females, mean age: 44.2 ±12.9 years) who underwent TNS for a GH secreting pituitary adenoma between 1980 and 2020, on regular follow-up at two Pituitary Units...

Somatic mutations in the ubiquitin specific peptidase 8 (USP8) gene have been associated with higher levels of somatostatin (SS) receptor subtype 5 (SSTR5) in adrenocorticotroph hormone (ACTH)-secreting pituitary neuroendocrine tumors (PitNETs). However, a correlation between the USP8 mutational status and favorable responses to pasireotide, the somatostatin multi-receptor ligand acting especially on SSTR5, has not been investigated yet. Here, we studied the impact of USP8 mut...

The mTOR inhibitor everolimus has been shown to display antimitotic effects on diverse neoplasms, including pituitary neuroendocrine tumors (PitNETs); however, its effect is reduced by an escape mechanism that increases AKT phosphorylation (P-AKT) leading to survival pathway activation. Dopamine receptor type 2 (DRD2) reduces p-AKT in some non-functioning PitNETs (NF-PitNETs) and in lactotrophs MMQ cells, through a α-arrestin 2-dependent mechanism. This study aim...

During the spring of 2020, a national lockdown was adopted in Italy to prevent COVID-19 pandemic spread. Restrictive measures have been associated with impaired psychological outcome in the general population. As patients with Cushing’s Syndrome (CS), including Cushing’s disease (CD), adrenal CS (ACS), and ectopic CS (ECS), are reportedly associated with a higher prevalence of anxiety, stress susceptibility, depression, and maniac episodes, during both active disease...

Neuroendocrine tumors (NETs) represent a heterogeneous group of malignancies with increasing incidence worldwide, due in part to enhanced awareness and diagnosis improvements. Surgery is often effective for local disease, whereas disseminated or metastatic disease require pharmacological treatment, which is not always successful. Pancreatic (Pan-NETs) and pulmonary (Lung-NETs) neuroendocrine tumors frequently express somatostatin receptors (SSTs), providing the target for trea...

The main target of pharmacological therapy for growth hormone (GH)-secreting pituitary tumors (GH-PitNET) is the somatostatin receptor type 2 (SST2). However, approximately half of patients treated with octreotide, an SST2 agonist, show a low response rate or are octreotide-resistant. Here we present mechanistic data that shows co-treatment with simufilam, a novel oral therapeutic candidate, enhances sensitivity to octreotide. We previously showed that the cytoskeleton protein...